Tonix Pharmaceuticals (TNXP) Surpasses $1 To Restore Lost Points Gained In August

One of the short-term growing biotech stocks Tonix Pharmaceuticals (TNXP) suddenly pops over 60% in the premarket on more than 20 million shares as its TNX-102 SL drug shows positive results in phase 2 of relief study for treating Fibromyalgia. 90% of participants were women as they get exposed to that disease most often. The number of women is increasing, so future revenue gets assured as the number of women almost dominating.

In July the stock has enjoyed 3x value as the company announced positive clinical trials. Tonix has also beat Q3 earnings expectations, as a result, investors spent a lot of money hoping the company soon starts providing regular dividends out of penny shares.

Tonix shares faced a very short-term jump in September attempting to revive again to show off the cheapest but reliable ones. So penny stock traders do not stay distant finding the stock isn’t going to give up and further move is highly expected amid ongoing drug development.

Related:  Rapidly Surging Stock To Watch: Splunk Inc (NASDAQ: SPLK)

Alex Krakowsky

Editor in Chief. Living in the era of dynamic tech change Alex decided to stay tuned in changes that make any person find comfort and adapt to new devices. Furthermore, gaming became his passion for spending leisure time with his close ones. Although, he has a degree in Business Administration (majoring in Finance) writing for technology and as well as finance has been one of the precious aspects of his life

Want Hot Stocks?    Yes. I Love Them No thanks